Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Saved in:
Bibliographic Details
Title: Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.
Authors: Lenz G; Department of Medicine A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany. Electronic address: georg.lenz@ukmuenster.de., Trněný M; First Faculty of Medicine, Charles University, Prague, Czech Republic., Burke JM; Sarah Cannon Research Institute at Rocky Mountain Cancer Centers, Aurora, CO, USA., Nowakowski GS; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Fox CP; School of Medicine, University of Nottingham, and Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK., Chiappella A; Fondazione IRCCS Istituto Nazionale dei Tumori, Hematology, Milan, Italy., Duell J; Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany., Jeon YW; Department of Hematology, Yeouido St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Cheah CY; Hollywood Private Hospital and University of Western Australia, Nedlands, WA, Australia., Westin J; MD Anderson Cancer Center, Houston, TX, USA., Ye JZ; American Oncology Network, Vista Oncology Division, Olympia, WA, USA., Caguioa PB; St Luke's Medical Center, Quezon, Philippines., Belada D; Department of Internal Medicine-Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic., Shin HJ; Division of Hematology-Oncology, Department of Internal Medicine, Research Institute of Medical Science, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea., Oh SY; Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea., Amorim S; Department of Hematology and Cellular Therapy, Hôpital Saint Vincent de Paul, Lille, France., Ku M; Department of Haematology, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia., Mocikova H; Department of Hematology, Third Faculty of Medicine, Charles University, and University Hospital Kralovske Vinohrady, Prague, Czech Republic., Jiménez JL; Department of Haematology and Hemotherapy, Hospital Ramón y Cajal, Universidad Alcalá Henares, IRYCIS, Madrid, Spain., Gaidano G; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont and AOU Maggiore della Carità, Novara, Italy., Rosenwald A; Institute of Pathology, University of Würzburg, Würzburg, Germany., Chiarle R; Division of Diagnostic Haematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy; Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy., Colucci P; Incyte Corporation, Wilmington, DE, USA., Ioannidis S; Incyte Biosciences International Sàrl, Morges, Switzerland., Cheng L; Incyte Corporation, Wilmington, DE, USA., Vitolo U; Candiolo Cancer Institute, FPO-IRCCS Candiolo, Turin, Italy.
Corporate Authors: frontMIND Study Investigators
Source: Lancet (London, England) [Lancet] 2026 Jun 20; Vol. 407 (10547), pp. 2528-2541. Date of Electronic Publication: 2026 May 30.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-547X
DOI:10.1016/S0140-6736(26)00866-4